Completed PHASE2 INTERVENTIONAL 3-arm NCT00192309

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

A Randomized, Open-Label, Placebo-Controlled Trial to Investigate the Kinetics of the Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent,Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Adults Aged 18 to <65 Years.

Sponsor: MedImmune LLC

Conditions Influenza

Interventions CAIV-T Placebo TIV

Updated 6 times since 2017 Last updated: Feb 13, 2012 Started: Sep 30, 2001 Primary completion: Dec 31, 2001 Completion: Dec 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Influenza and is currently completed. MedImmune LLC leads this study, which shows 6 recorded versions since 2001 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Data source: MedImmune LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stamford, United States